Evidence map›Paper›PMID 22081310›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012

Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity.

Harumi Inoue, Yuji Miyazaki, Kentaro Kikuchi, Noriaki Yoshida, Fumio Ide, Yoshihiro Ohmori, Akihito Tomomura, Hideaki Sakashita, Kaoru Kusama

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Podoplanin in Inflammation and Cancer.International journal of molecular sciences · 2019
    Review
  5. Article
  6. Article
  7. Article
  8. Expression of Podoplanin in Laryngeal Squamous Cell Carcinoma and Dysplasia.Journal of clinical and diagnostic research : JCDR · 2017
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Podoplanin expressing cancer-associated fibroblasts in oral cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  15. Article
  16. Krüppel-like factor 5: a novel biomarker for lymph node metastasis and recurrence in supraglottic squamous cell laryngeal carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Harumi InoueDivision of Pathology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Keyakidai, Sakado, Saitama 350-0283, Japan. harumi-i@dent.meikai.ac.jp
Yuji Miyazaki
Kentaro Kikuchi
Noriaki Yoshida
Fumio Ide
Yoshihiro Ohmori
Akihito Tomomura
Hideaki Sakashita
Kaoru Kusama
Meikai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human podoplanin, a type-1 transmembrane sialomucin-like glycoprotein, is involved in cell migration, tumor cell invasion, and metastasis. However, the role of the protein in squamous cell carcinoma (SCC) has been unclear and immunohistochemical reactivity for podoplanin differs from organ-to-organ. In the present study, immunohistochemical and molecular biological analyses were performed to examine the importance of podoplanin expression in oral precancerous and cancerous lesions and metastases. We immunohistochemically investigated the expression of podoplanin in 103 precancerous lesions, 69 primary oral squamous cell carcinomas (OSCCs), and 32 metastases, and that of E-cadherin and vimentin in primary OSCCs with metastasis. Furthermore, human OSCC-derived cell lines preincubated with fibrous growth factor-basic, epidermal growth factor (EGF), and tumor growth factor-β1 were subjected to real-time reverse transcription polymerase chain reaction. Immunoreactivity for podoplanin was detected in 89 (86.4%) of the precancerous lesions and the intensity was correlated with the degree of epithelial dysplasia (P = 0.016). Enhanced podoplanin expression was observed in 66 (95.7%) of the OSCCs and was significantly associated with a poor pathologic grade of differentiation (P = 0.020). Epithelial-mesenchymal transition was observed in 18 (58.1%) of the primary OSCCs with metastasis to regional lymph nodes. Messenger RNA for podoplanin was markedly increased after treatment with EGF in three OSCC cell lines. The present findings suggest that podoplanin is associated with tumor development via the oral dysplasia-carcinoma sequence and could be involved in a signaling pathway governing tumor growth and invasion in OSCC.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellFemaleHumansMaleMembrane GlycoproteinsMouthMouth NeoplasmsNeoplasm GradingNeoplasm InvasivenessPodoplaninPrecancerous ConditionsBiomarkers, TumorMembrane GlycoproteinsPDPN protein, humanPodoplanin

Identifiers

PMID22081310
OpenAlexW2027689541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.